Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia.

Objective: For investigating the efficacy and mechanism of Roxadustat + oral iron in the treatment of elderly chronic kidney disease (CKD) complicated with anemia. Methods: A total of 100 elderly patients with CKD and anemia admitted to our hospital between April 2020 and December 2021 were enrolled as research subjects, and the patients were assigned to control group (Con group, n = 50) or experimental group (Exp group, n = 50). The patients in the Con group were given oral iron, and those in the Exp group were given Roxadustat capsule based on the Con group. Both groups were given subcutaneous injection of recombinant human erythropoietin. The clinical efficacy, anemia indexes, iron metabolism indexes, inflammatory indexes, and adverse reactions were compared between the two groups. Results: The Exp group showed a notably higher treatment effective rate than the Con group (P < 0.05). After treatment, the anemia indexes, iron metabolism indexes, and inflammatory indexes in the Exp group were notably better than those in the Con group (P < 0.05). The Exp group showed a notably lower incidence of adverse reactions during treatment than the Con group (P < 0.05). Conclusion: Roxadustat plus oral iron yields a pronounced clinical efficacy in the therapy of elderly patients with CKD and anemia.

RuO2-x decorated CoSnO3 nanoboxes as a high performance cathode catalyst for Li-CO2 batteries.

Rechargeable Li-CO2 batteries contribute towards lessening fossil fuel depletion and alleviating the "greenhouse effect". However, more efforts must be made to figure out the critical problems of a high overpotential and poor cycling stability associated with this type of battery. Here, CoSnO3/RuO2-x nanocomposites were employed as an efficient air cathode for Li-CO2 batteries, which can lower the overpotential and improve their long-term cycling performance (around 145 cycles) remarkably.